NGFR/p75 neurotrophin receptor (p75NTR), Mouse Monoclonal Antibody

As low as US$327.00
Only %1 left
Catalog Number
M-1818

    Product Info

  • Product Name NGFR/p75 neurotrophin receptor (p75NTR), Mouse Monoclonal Antibody
  • Product Description google
    Mouse anti-p75 neurotrophin receptor (p75NTR) Monoclonal Antibody (Unconjugated), suitable for FC, ICC, IHC-Frozen, WB, IP, Immunopanning.
  • Alternative Names Low-affinity nerve growth factor receptor; NGF receptor; Gp80-LNGFR; p75 ICD; Low affinity neurotrophin receptor p75NTR; CD271
  • Application(s) FC, ICC, IHC-Frozen, Immunopanning, IP, WB
  • Antibody Host Mouse
  • Antibody Type Monoclonal
  • Specificity Human, reacts with human, mouse and rat. Cross-reactivity with other species not tested but expected.This antibody is specific for NGFR/p75NTR as demonstRated by western blotting and immunprecipitation. The antibody recognizes extracellular p75NTR under non-reducing conditions.
  • Species Reactivity Human, Mouse, Rat
  • Immunogen Description Recombinant extracellular domain (amino acids 29-250) of human NGFR/p75NTR protein with N-terminal His-tag.
  • Conjugate Unconjugated
  • Purity Description Protein A purified IgG
  • Regulatory Status For research use only.

    Specifications

  • Product Description
    Mouse anti-p75 neurotrophin receptor (p75NTR) Monoclonal Antibody (Unconjugated), suitable for FC, ICC, IHC-Frozen, WB, IP, Immunopanning.
  • Related Products NGFR/p75 neurotrophin receptor (p75NTR), Mouse Monoclonal Antibody (FITC)
    NGFR/p75 neurotrophin receptor (p75NTR), Mouse Monoclonal Antibody (ATTO 488)
  • Application(s) FC, ICC, IHC-Frozen, Immunopanning, IP, WB
  • Application Details Flow Cytometry: 5-20 µg/mL.
    Western Blotting: 0.5-2.0 µg/mL, non-reducing conditions only (no DTT or beta-mercaptoethanol).
    Immunoprecipitation: lysate dependent. 10 ug per 200-500 ug total protein.
    Immunopanning: 1-5 µg/mL.
    Immunocytochemistry: 1-5 µg/mL. Staining is strongest in non-fixed cells, light fixation is tolerable.
    Immunohistochemistry: fresh, acetone fixed sections only, epitope is fixation sensitive. Not suitable in formalin-fixed, paraffin (FFPE) embedded tissues.
    Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
  • Target NGFR/p75 neurotrophin receptor (p75NTR)
  • Specificity Human, reacts with human, mouse and rat. Cross-reactivity with other species not tested but expected.This antibody is specific for NGFR/p75NTR as demonstRated by western blotting and immunprecipitation. The antibody recognizes extracellular p75NTR under non-reducing conditions.
  • Target Host Species Human
  • Species Reactivity Human, Mouse, Rat
  • Antibody Host Mouse
  • Antibody Type Monoclonal
  • Antibody Isotype IgG2a
  • Clone Name 8J2
  • Conjugate Unconjugated
  • Immunogen Description Recombinant extracellular domain (amino acids 29-250) of human NGFR/p75NTR protein with N-terminal His-tag.
  • Purity Description Protein A purified IgG
  • Format Lyophilized from a solution containing PBS buffer pH 7.2-7.6 with 0.1% trehalose, without preservatives.
  • Reconstitution Instructions Spin vial briefly before opening. Reconstitute in 100 µL sterile-filtered, ultrapure water to achieve a concentration of 1 mg/mL. Centrifuge to remove any insoluble material. Final buffer contains no preservatives.
  • Storage Instructions Store lyophilized antibody at 2-8°C. After reconstitution divide into aliquots and store at -20°C for long-term storage. Store at 2-8°C short-term (up to 4 weeks) with an appropriate antibacterial agent. Avoid repetitive freeze/thaw cycles.
  • Batch Number Please see item label.
  • Expiration Date 12 months after date of receipt (unopened vial).
  • Alternative Names Low-affinity nerve growth factor receptor; NGF receptor; Gp80-LNGFR; p75 ICD; Low affinity neurotrophin receptor p75NTR; CD271
  • Uniprot Number P08138
  • Uniprot Number/Name P08138 (TNR16_HUMAN)
  • Scientific Background p75NTR (CD271) was originally discovered as a low affinity nerve growth factor receptor (NGFR). Later it was found that it was the receptor for all neurotrophins, including NGF, BDNF, NT3 and NT4/5. It mediates signals of neurotrophins for neuronal survival, apoptosis, neurite outgrowth and synaptic plasticity. Recently, it has been revealed that p75NTR not only acts as the receptor for neurotrophins but also the receptor for many other pathological ligands such as prions, rabies virus and amyloid beta. p75NTR also acts as a co-receptor for NOGO which mediates inhibitory signals of myelin associated protein. p75NTR is highly expressed in a number of non-neuronal and neuronal cells including motor neurons during development and also in damaged neurons. Recent research proposes the extracellular domain of p75NTR as a biomarker for monitoring the progression of motor neuron disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig's Disease. SUBUNIT: Homodimer; disulfide-linked. Interacts with p75NTR-associated cell death executor. Interacts with NGFRAP1/BEX3.
  • Shipping Temperature 25°C (ambient)
  • UNSPSC CODE 41116161
  • Regulatory Status For research use only.

    Images, Protocols & SDS

  • Left: Analysis of p75NTR expression in human and rodent RIPA cell lysates by Western Blotting. Mouse antibody to p75NTR clone 8J2 (M-1818-100) and clone MLR2 (M-009-100) detect p75NTR-IR at ~50-60 kDa in mouse p75NTR-transfected cells (A), but not in non-transfected control cells (B). p75NTR-IR is also observed in human SH-SY5Y (C) and rat C6 (D) cell lysates. Dependent on cell lysate, dimers or trimers (~150 kDa) of p75NTR are detected (Anastasia et al., 2015). 50 ug of protein were loaded per lane. WB Method: SDS-PAGE: 4-12%, non-reducing conditions; Transfer: Tris-Glycine buffer; Membrane: nitrocellulose (0.45 um); Blocking: 5% skim milk in TBST, 1 hour at RT; Primary antibody: 1 µg/mL, overnight at 4°C; Secondary antibody: anti-mouse-HRP (1/6000) 1 hour at RT; Detection: Chemiluminiscence. Right: Immunoprecipitation of p75NTR from rat C6 cell lysate and detection by Western Blotting. Mouse antibody to p75NTR clone 8J2 (M-1818-100) and clone MLR2 (M-009-100) precipitate bands at the expected molecular weight of ~50-60 kDa for p75NTR (A). No p75NTR-IR is observed in remaining supernatant (B) or control (Protein G only, C). IP Method: C6 lysates were prepared in non-denaturing lysis buffer and pre-cleared with Protein G agarose beads (40 uL bead slurry per 1 mg total protein). Cleared lysate was then incubated with either M-1818-100 or M-009-100 (10 ug antibody per 200 ug total protein), and immune complexes bound by Protein G agarose (10 uL). Precipitated p75NTR was eluted off the beads and antibody by heating and addition of SDS-PAGE sample buffer. WB Method: as above, with primary goat anti-p75NTR (1 µg/mL) antibody and secondary anti-sheep-HRP (1/6000) antibody. Detection: Chemiluminiscence.

  • Binding analysis of M-1818-100 (8J2) and M-009-100 (MLR2) antibodies by 1-site ELISA on human and mouse p75NTR protein. Clone 8J2 detects both, human and mouse p75NTR proteins with higher affinity than clone MLR2.


    Analysis of p75NTR expression in human SH-SY5Y and rat C6 cell lines by Flow Cytometry. Blocking: 200 µg/mL sheep IgG, 30 minutes on ice; Primary antibody: Mouse monoclonal antibodies to p75NTR cat # M-1818-100, clone 8J2 (red) and M-009-100, clone MLR2 (black), ~2 µg per 10^6 cells, for 60 minutes on ice, Secondary antibody: Goat anti-mouse-PE (1:100 dilution), 20 minutes in dark on ice. Negative control: Non-specific Control IgG, clone X63 (cat # M-1249-200, black dashed). Data and results were generated using Orflo MoxiflowTM instrument and protocols.


    Analysis of membrane p75NTR expression in rat C6 cells by Immunocytochemistry. Non-permeabilized cells were stained with mouse antibodies to p75NTR clones 8J2 (M-1818-100) and MLR2 (M-009-100) either on ice without fixation (top panel), or after fixation with 4% formaldehyde (bottom panel). Both antibodies reveal punctuate membrane staining of p75NTR receptor. This staining is specific, because negative mouse control antibody clone X63 (M-1249-100) does not show immunoreactivity. Method: Primary antibodies: 2 µg/mL, 1 hour incubation; Blocking: 10% normal horse serum, 30 minutes; Fixation: 4% formaldehyde, 10 minutes, either before application of primary antibody (bottom panel) or after application of primary antibody (upper panel); Secondary antibody: donkey anti-mouse-CF488A (2 µg/mL), 1 hour incubation. Cell nuclei were stained with Hoechst dye (blue), 1:1,000, 20 minutes at room temperature. Magnification: 100x.


    p75NTR staining (green) in rat trigeminal ganglion cells by Immunocytochemistry. Primary antibody dilution: 1:100. Image courtesy of QBM Cell Science.

    Citations & References

  • Specific References

    Salehi S et al. (2023) Cytosolic Ptbp2 modulates axon growth in motoneurons through axonal localization and translation of Hnrnpr Nat Commun. 14(1):4158. Application: Mouse, Immunopanning.

    Hennlein L et al. (2023) Plastin 3 rescues cell surface translocation and activation of TrkB in spinal muscular atrophy J Cell Biol. [Epub ahead of print] Application: Mouse, Immunopanning.

    Hulme AJ et al. (2020) Molecular and Functional Characterization of Neurogenin-2 Induced Human Sensory Neurons . Front Cell Neurosci. 14:600895 Application: Human, ICC(IF).

  • General References Matusica D et al. (2008). Characterisation and use of the NSC-34 cell liner for study of nerurotrophin receptor trafficking. J. Neurosci. Res. 86(3) pp. 553-65.

    Huh CY et al. (2008). Chronic exposure to nerve growth factor increases acetylcholine and glutamate release from cholinergic neurons of the rat medial septum and diagonal band of Boca via mechanisms mediated bu p75NTR. J. Neurosci. 28(6) pp. 1404-9.

    Lagares A et al. (2007). Primary sensory neuron addition in the adult rat trigeminal ganglion: evidence for neural crest glio-neuronal precursor maturation. J. Neurosci. 27(30) pp. 7939-53.

    DiStefano & Johnson (1988). Identification of a truncated form of the nerve growth factor receptor. Proc Natl Acad Sci U S A. 1988 Jan;85(1):270-4.